It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Circular RNAs (circRNAs) are increasingly gaining importance and attention due to their diverse potential functions and their value as diagnostic biomarkers (disease specific). This study aims to explore the novel mechanisms by which exosome-contained circRNAs promote tumor development and metastasis in TNBC. We identified increased circRNA circPSMA1 in TNBC cells, their exosomes, and serum exosomes samples from TNBC patients. The overexpression of circPSMA1 promoted TNBC cell proliferation, migration, and metastasis both in vitro and in vivo. Moreover, we investigated the tumor-infiltrating immune cells (TICs) or stromal components in immune microenvironment (IME), and identified the significant differences in the immune cells between TNBC and non-TNBC samples. Mechanistically, circPSMA1 acted as a “miRNAs sponge” to absorb miR-637; miR-637 inhibited TNBC cell migration and metastasis by directly targeted Akt1, which recognized as a key immune-related gene and affected downstream genes β-catenin and cyclin D1. Subsequent co-culture experiments also demonstrated that exosomes from TNBC carrying large amounts of circPSMA1 could transmit migration and proliferation capacity to recipient cells. Kaplan–Meier plots showed that high expression of Akt1 and low expression of mir-637 are highly correlated with poor prognosis in patients with lymph node metastasis of TNBC. Collectively, all these results reveal that circPSMA1 functions as a tumor promoter through the circPSMA1/miR-637/Akt1-β-catenin (cyclin D1) regulatory axis, which can facilitate the tumorigenesis, metastasis, and immunosuppression of TNBC. Our research proposes a fresh perspective on novel potential biomarkers and immune treatment strategies for TNBC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 the First Affiliated Hospital of Nanjing Medical University, Department of General Surgery, Nanjing, P.R. China (GRID:grid.412676.0) (ISNI:0000 0004 1799 0784)
2 The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, P.R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984); Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Center of Clinical Laboratory, Nanjing, P.R. China (GRID:grid.452509.f) (ISNI:0000 0004 1764 4566)
3 Nanjing Medical University, Department of Obstetrics and Gynecology, Maternity and Child Health Care Hospital, Nanjing, P.R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)
4 The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, P.R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)
5 the Affiliated Huai’an Hospital of Xuzhou Medical University, the Second People’s Hospital of Huai’an, Department of Thyroid and Breast Surgery, Huai’an, P.R. China (GRID:grid.470132.3)